Prognostic value of plasma Aβ1-40 for Alzheimer's disease

Objective: To investigate the clinical significance of plasma p-amyloid 1-40 (A beta 1-40) in patients with Alzheimer's disease (AD). Methods: In this retrospective study, the clinical data of 305 patients, with or without Alzheimer's disease (AD), who were treated at the Affiliated Hospital of Youjiang Medical University for Nationalities between January 2018 and December 2021 were analyzed. Patients were divided into two groups: an AD group (n=147) and a non-AD group (without AD, n=158 cases). Blood test indices, including serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (CRE), high-sensitivity C-reactive protein (hsCRP), and plasma beta-amyloid 1-40 were collected and compared between the two groups. Results: The plasma beta-amyloid 1-40 in the AD group was (3.71 +/- 3.45) mol/L, which was significantly higher than (2.8 +/- 1.35) mmol/L in the non-AD group (P<0.05). Similarly, hsCRP expression was significantly higher in the AD group than that in the non-AD group (P<0.05). There were no significant differences in AST, ALT, UA, T-tau, NFL or Cr levels between the two groups (all P>0.05). Moreover, univariate regression analysis showed that plasma beta-amyloid 1-40 and hsCRP were significantly correlated with AD. Multiple regression analysis demonstrated that plasma p-amyloid 1-40 (P<0.0001) and hsCRP (P=0.002) were independent predictors of AD. Conclusion: Plasma p-amyloid 1-40 and hsCRP are closely related to AD, and may serve as important clinical predictors of AD.